Recent advances in the role of RNA-binding protein, tristetraprolin, in arthritis

References

• McInnes IB, Buckley CD, Isaacs JD. Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nat Rev Rheumatol. 2016;12:63–68.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038.
   PubMed Web of Science ®Google Scholar
• Hao S, Baltimore D. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat Immunol. 2009;10:281–288.
   PubMed Web of Science ®Google Scholar
• Anderson P. Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol. 2010;10:24–35.
   PubMed Web of Science ®Google Scholar
• Leppek K, Schott J, Reitter S, et al. Roquin promotes constitutive mRNA decay via a conserved class of stemloop recognition motifs. Cell. 2013;153:869–881.
   PubMed Web of Science ®Google Scholar
• Matsushita K, Takeuchi O, Standley DM, et al. Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay. Nature. 2009;458:1185–1190.
   PubMed Web of Science ®Google Scholar
• Mino T, Murakawa Y, Fukao A, et al. Regnase-1 and Roquin regulate a common element in inflammatory mRNAs by spatiotemporally distinct mechanisms. Cell. 2015;161:1058–1073.
   PubMed Web of Science ®Google Scholar
• Takeuchi O. Endonuclease Regnase-1/monocyte chemotactic protein-1-induced protein-1 (MCPIP1) in controlling immune responses and beyond. WIREs RNA. 2018;9:e1449.
   Google Scholar
• Turner M, Díaz-Muñoz MD. RNA-binding proteins control gene expression and cell fate in the immune system. Nat Immunol. 2018;19:120–129.
   PubMed Web of Science ®Google Scholar
• Halees AS, El-Badrawi R, Khabar KS. ARED Organism: expansion of ARED reveals AU-rich element cluster variations between human and mouse. Nucleic Acids Res. 2007;36:D137–D140.
   PubMed Web of Science ®Google Scholar
• Ivanov P, Anderson P. Post-transcriptional regulatory networks in immunity. Immunol Rev. 2013;253:253–272.
   PubMed Web of Science ®Google Scholar
• Taylor GA, Carballo E, Lee DM, et al. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity. 1996;4:445–454.
   PubMed Web of Science ®Google Scholar
• Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science. 1998;281:1001–1005.
   PubMed Web of Science ®Google Scholar
• Brooks SA, Blackshear PJ. Tristetraprolin (TTP): interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim Biophys Acta. 2013;1829:666–679.
   PubMed Web of Science ®Google Scholar
• Fabian MR, Frank F, Rouya C, et al. Structural basis for the recruitment of the human CCR4-NOT deadenylase complex by tristetraprolin. Nat Struct Mol Biol. 2013;20:735–739.
   PubMed Web of Science ®Google Scholar
• Zhu W, Brauchle MA, Di Padova F, et al. Gene suppression by tristetraprolin and release by the p38 pathway. Am J Physiol Lung Cell Mol Physiol. 2001;281:L499–L508.
   PubMed Web of Science ®Google Scholar
• Mahtani KR, Brook M, Dean JL, et al. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol. 2001;21:6461–6469.
   PubMed Web of Science ®Google Scholar
• Stoecklin G, Stubbs T, Kedersha N, et al. MK2-induced tristetraprolin: 14-3-3 complexes prevent stress granule association and ARE-mRNA decay. Embo J. 2004;23:1313–1324.
   PubMed Web of Science ®Google Scholar
• Chrestensen CA, Schroeder MJ, Shabanowitz J, et al. MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J Biol Chem. 2004;279:10176–10184.
   PubMed Web of Science ®Google Scholar
• Hitti E, Iakovleva T, Brook M, et al. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol. 2006;26:2399–2407.
   PubMed Web of Science ®Google Scholar
• Brook M, Tchen CR, Santalucia T, et al. Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol Cell Biol. 2006;26:2408–2418.
   PubMed Web of Science ®Google Scholar
• Sun L, Stoecklin G, Van Way S, et al. Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-α mRNA. J Biol Chem. 2006;282:3766–3777.
   Web of Science ®Google Scholar
• Prabhala P, Bunge K, Ge Q, et al. Corticosteroid-induced MKP-1 represses pro-inflammatory cytokine secretion by enhancing activity of tristetraprolin (TTP) in ASM cells. J Cell Physiol. 2016;231:2153–2158.
   PubMed Web of Science ®Google Scholar
• Smoak K, Cidlowski JA. Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. Mol Cell Biol. 2006;26:9126–9135.
   PubMed Web of Science ®Google Scholar
• Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J. 1991;10:4025–4031.
   PubMed Web of Science ®Google Scholar
• Carballo E, Blackshear PJ. Roles of tumor necrosis factor-alpha receptor subtypes in the pathogenesis of the tristetraprolin-deficiency syndrome. Blood. 2001;98:2389–2395.
   PubMed Web of Science ®Google Scholar
• Patial S, Blackshear PJ. Tristetraprolin as a therapeutic target in inflammatory disease. Trends Pharmacol Sci. 2016;37:811–821.
   PubMed Web of Science ®Google Scholar
• Patial S, Curtis AD, Lai WS, et al. Enhanced stability of tristetraprolin mRNA protects mice against immune-mediated inflammatory pathologies. Proc Natl Acad Sci USA. 2016;113:1865–1870.
   PubMed Web of Science ®Google Scholar
• Ross EA, Smallie T, Ding Q, et al. Dominant suppression of inflammation via targeted mutation of the mRNA destabilizing protein tristetraprolin. J Immunol. 2015;195:265–276.
   PubMed Web of Science ®Google Scholar
• Matsumoto I, Staub A, Benoist C, et al. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science. 1999;286:1732–1735.
   PubMed Web of Science ®Google Scholar
• Ross EA, Naylor AJ, O'Neil JD, et al. Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression. Ann Rheum Dis. 2017;76:612–619.
   Web of Science ®Google Scholar
• Clark AR, Dean JL. The control of inflammation via the phosphorylation and dephosphorylation of tristetraprolin: a tale of two phosphatases. Biochem Soc Trans. 2016;44:1321–1337.
   PubMed Web of Science ®Google Scholar
• Tsutsumi A, Suzuki E, Adachi Y, et al. Expression of tristetraprolin (G0S24) mRNA, a regulator of tumor necrosis factor-alpha production, in synovial tissues of patients with rheumatoid arthritis. J Rheumatol. 2004;31:1044–1049.
   Web of Science ®Google Scholar
• Arthur JS, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol. 2013;13:679–692.
   PubMed Web of Science ®Google Scholar